Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 14Carcinoid Tumor 5Gastro-enteropancreatic neuroendocrine tumor 4Acromegaly 4Serotonin Syndrome 2Pituitary Neoplasms 2Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Prostatic Neoplasms 1Pheochromocytoma 1Peritoneal Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neuroendocrine Tumors in Lung 1Neoplastic Cells, Circulating 1Neoplasms 1Intestinal Obstruction 1Growth Hormone-Secreting Pituitary Adenoma 1Gigantism 1Gastrointestinal Neoplasms 1Flushing 1Endocrine Tumors 1Diarrhea 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Heart Disease 1Adenoma, Islet Cell 1

Interventions

telotristat ethyl 5lanreotide 2telotristat 1pasireotide 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Random Allocation 1Panitumumab 1Octreotide 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Serotonin Syndrome × lanreotide × Clear all
NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn
Endocrine

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡